Day: December 22, 2019

BEIJING, China and CAMBRIDGE, Mass., Dec. 22, 2019 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the China National Medical Products Administration (NMPA) has accepted a supplemental new drug application (sNDA) for REVLIMID® (lenalidomide), in combination with rituximab, for the treatment of patients with relapsed or refractory indolent lymphoma (follicular lymphoma or marginal zone lymphoma). REVLIMID was first approved in China in 2013 for the treatment of multiple myeloma in combination with dexamethasone, in adult patients who have received at least one prior therapy, and the label for the combination was expanded...

NEW YORK, Dec. 22, 2019 (GLOBE NEWSWIRE) — Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call to review the top line results from the Phase 3 CONDOR trial of PyL™ (18F-DCFPyL) in men with biochemical recurrence of prostate cancer on Monday, December 23, 2019, at 8:00 a.m. ET.  The Company intends to issue a press release announcing the top line results of the CONDOR trial on the same day in advance of the conference call.To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (international) and reference conference ID 9165086. A live webcast will be available in the Media Center of the Progenics website, www.progenics.com, and a...

The shareholders of Anoto Group AB (publ) (the “Company”) are hereby invited to attend the Extraordinary General Meeting (the “EGM”) to be held on Monday, 13 January 2020 at 9 a.m. at the premises of Setterwalls Advokatbyrå, Sturegatan 10 in Stockholm, Sweden. Notification of participationShareholders wishing to attend the EGM must  be entered as shareholders in the share register maintained by Euroclear Sweden AB no later than on Tuesday, 7 January 2020,notify the Company of their intention to participate no later than on Thursday, 9 January 2020.Attendance is to be notified by telephone +44 125 677 4400 or by e-mail to EGM@anoto.com. The notification should state name, social security number/corporate identification number and registered number of shares. To facilitate admittance to...

Aktieägarna i Anoto Group AB (publ) (“Bolaget”), kallas härmed till extra bolagsstämma att äga rum måndagen den 13 januari 2020, kl. 09.00 i Setterwalls Advokatbyrås lokaler med adress Sturegatan 10 i Stockholm. Rätt att delta och anmälanAktieägare som önskar att deltaga i bolagsstämman ska dels vara registrerad i eget namn i den av Euroclear Sweden AB förda aktieboken för Bolaget senast tisdagen den 7 januari 2020,dels anmäla sitt deltagande till Bolaget senast torsdagen den 9 januari 2020.Anmälan om deltagande i bolagsstämman ska ske per telefon till +44 125 677 4400 eller per e-post till EGM@anoto.com. Vid anmälan ska namn, personnummer/organisationsnummer samt registrerat aktieinnehav uppges. Fullmakter, registreringsbevis...

Aarhus, den 22. december 2019NASDAQ OMX Copenhagen A/SMeddelelse nr. 20 /2019AGF A/S forlænger samarbejdet med cheftræner David NielsenAGF A/S har dags dato forlænget samarbejdet med cheftræner David Nielsen med tre år. Den nye aftale gælder således til 30. juni 2023.David Nielsen har været cheftræner i AGF siden 30. september 2017.Med venlig hilsenAGF A/SJacob NielsenAdm. direktørFor yderligere oplysninger kontakt kommunikationschef Søren Højlund Carlsen på tlf. 411 411 52Vedhæftet filSelskabsmeddelelse nr 20-2019 AGF AS forlænger samarbejdet med cheftræner David Nielsen